Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EBT: 2009-2024

Historic EBT for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$18.6 million.

  • Lineage Cell Therapeutics' EBT fell 13.96% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 59.75%. This contributed to the annual value of -$18.6 million for FY2024, which is 20.19% up from last year.
  • Lineage Cell Therapeutics' EBT amounted to -$18.6 million in FY2024, which was up 20.19% from -$23.3 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' EBT ranged from a high of -$18.6 million in FY2024 and a low of -$43.3 million during FY2021.
  • For the 3-year period, Lineage Cell Therapeutics' EBT averaged around -$22.6 million, with its median value being -$23.3 million (2023).
  • Per our database at Business Quant, Lineage Cell Therapeutics' EBT plummeted by 97.36% in 2021 and then soared by 40.35% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' EBT (Yearly) stood at -$21.9 million in 2020, then slumped by 97.36% to -$43.3 million in 2021, then soared by 40.35% to -$25.8 million in 2022, then grew by 9.80% to -$23.3 million in 2023, then climbed by 20.19% to -$18.6 million in 2024.